SEC Form 4 · accession 0001493152-17-001082
Adhera Therapeutics, Inc. · ATRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph W. Ramelli
Officer — Chief Executive Officer
Period of report
Feb 2, 2017
Accepted (ET)
Feb 3, 2017 · 12:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000737207
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 2, 2017 | A | 100,000 | $0.00 | A | 307,603 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted shares of common stock awarded to the reporting person on February 2, 2017 pursuant to the employment letter dated February 2, 2017 between the reporting person and the issuer. Such restricted shares shall vest upon the first execution and delivery by the issuer following the date of the employment letter of a definitive agreement involving the licensing by the issuer its Smarticles-based liposomal delivery technology. The restricted shares were issued under the issuer's 2014 Long-Term Incentive Plan.